This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. F.A.C.C.
Coronary CT angiography for the suspected progression of known coronaryarterydisease in a 56-year-old female patient. mm (green outline) section thickness show the respective calcified plaque (arrowheads) and coronary stenosis (inset images). Curved multiplanar reconstructions with 0.6-mm
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronaryartery inflammation and accurately predict cardiac events. fold higher risk for cardiac mortality and 5.5-fold
It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronaryarterydisease. “We He is the author of over 150 articles, book chapters, abstracts and other publications on advanced imaging technologies. Barcelona, Spain.
Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. After implantation, the locked phase establishes the maximum flow lumen and restores blood flow to treat symptoms of coronaryarterydisease (CAD).
a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT) code beginning January 1, 2024. milla1cf Tue, 01/23/2024 - 13:44 January 23, 2024 — HeartFlow, Inc. ,
Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronaryarterydisease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue. vs. 28.7%; P=0.006). in the coming months.
a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ).
15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-CoronaryPlaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S. The LCDs have a future effective date of Nov.
6 Also in 2023, HeartFlow released its RoadMap Analysis which helps identify and quantify narrowings in the coronaryarteries and has demonstrated a 25% faster CCTA read time. We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMap Analysis.
a leader in AI-driven healthcare technology, announced the launch of the DECIDE Registry, the largest prospective registry of its kind, with the first site initiated, Cone Health Care. 2 “Data from the DECODE study shows the value of using Plaque Analysis. 2 “Data from the DECODE study shows the value of using Plaque Analysis.
a provider of AI technology for coronaryarterydisease (CAD) management, recently introduced its new brand identity reflecting its focus on delivering clarity, precision and confidence in the prevention, diagnosisand treatment of CAD. References Centers for Disease Control and Prevention. Heart Disease Facts.
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. As we’ve seen with their recent Medicare and CPT I code approvals, this technology is both valuable and ready today in the fight against heart disease.”
Food and Drug Administration (FDA) 510(k) clearance of its CaRi-Plaquetechnology, an AI-assisted image analysis application to aid the diagnosis of coronaryarterydisease (CAD). For decades, heart disease has been treated reactively, waiting for symptoms to appear before taking action. But with AI, we can change that.
a leader in non-invasive artificial intelligence (AI) heart care solutions, announced that the data from its REVEALPLAQUE study , highlighting the accuracy of its Plaque Analysis, was published in the European Heart Journal Cardiovascular Imaging. 1 Heart disease is the leading cause of death for both men and women.²
A family history of heart disease often indicates that genetic factors might be at play. Common Heart Diseases with Genetic Links CoronaryArteryDisease (CAD): CAD occurs when the arteries supplying blood to the heart become narrowed or blocked.
Improved patient safety with reduced radiation and contrast load Enhancing patient safety is a pivotal aspect of advanced cardiac imaging technology. By employing advanced scanning technology, healthcare providers can ensure patients undergo diagnostic procedures with minimized risks.
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronaryarterydisease (CAD), historically linked with a mortality rate exceeding 50 percent within five years.
mg tablets), together with Caristo Diagnostics , a leading cardiac disease diagnostics company with the novel CaRi-Heart technology to visualize and quantify coronary inflammation, announced today their collaboration to improve awareness and clinical education about the central role of inflammation in coronaryarterydisease.
CT coronary angiography, in addition to a CT CAC, is arguably the best test for estimating whether someone has evidence of coronaryarterydisease and what that means for their near-term risk of a heart attack. Mixed Plaque - A combination of both calcified and NON-calcified plaque.
Technological advancements have revolutionized the medical industry; now, portable ECG devices are also available. Coronaryarterydisease Excessive cholesterol builds up plaque that blocks the arteries supplying blood to the heart. ECG machine can also help diagnose coronaryarterydisease.
Data confirm the use of FFR CT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronaryarterydisease. The prospective data with long-term follow-up in ADVANCE-DK alongside Plaque Analysis data gave us far more than that.
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Personalized Cardiometabolic Care TRANSFORM Program for CoronaryArteryDisease (CAD) : The TRANSFORM program focuses on atherosclerosis-based care strategies rather than traditional risk-based approaches.
Retired NFL players Joel Dreessen and Le-Lo Lang will be among the first individuals in the registry to receive a coronaryarterydisease (CAD) assessment with HeartFlows AI-driven technology. Cardiovascular diseases are the leading cause of death in the United States and worldwide. 22, 2025 -- HeartFlow, Inc. ,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content